Stepwise Beta Cell Differentiation for Single-Hormone Insulin Expression

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Existing methods for differentiating human embryonic stem cells into functional pancreatic beta cells have fallen short of producing cells with characteristics of mature beta cells, including expression of single hormonal insulin, correct processing of proinsulin, and appropriate insulin release in response to glucose, while previous reports often result in polyhormonal cells that are non-functional.

Innovation Solution

A stepwise differentiation method involving culturing pluripotent cells in medium supplemented with specific growth factors and inhibitors, including TGF-B ligand, WNT activator, FGF ligand, shh inhibitor, PKC activator, TGF-B inhibitor, and retinoid, with precise timing and glucose concentration, to generate a population of pancreatic beta cells expressing PDX-1 and NKX6.1, and lacking SOX2 and CDX2 expression.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Manufacturing precision

If conventional differentiation methods are used, then some pancreatic cells can be generated, but the cells are polyhormonal and non-functional rather than single hormonal insulin-positive mature beta cells

Engineering Contradiction:
Improvecell differentiation precisionVSAvoidcell functionality
Core Design Contradiction:
Manufacturing precisionVSReliability

Solution Approach 1:

The differentiation process is divided into multiple discrete stages (definitive endoderm formation, foregut endoderm specification, pancreatic endoderm commitment, and beta cell differentiation), each with specific growth factors and inhibitors applied sequentially. This segmentation allows precise control over cellular identity at each step, preventing polyhormonal differentiation and ensuring functional maturity.

Inventive Principle:
Principle #1Segmentation

Solution Approach 2:

Specific transcription factors and signaling pathways are activated in advance at defined stages to prepare cells for subsequent differentiation steps. For example, PDX1 and NKX6.1 are induced at appropriate times to commit cells to the beta cell lineage before final differentiation, ensuring functional maturity rather than producing non-functional polyhormonal cells.

Inventive Principle:
Principle #10Preliminary action

2Productivity

If differentiation is accelerated, then more cells can be produced faster, but the cells lack mature beta cell characteristics and functional properties

Engineering Contradiction:
Improvecell production rateVSAvoidmature beta cell characteristics
Core Design Contradiction:
ProductivityVSManufacturing precision

Solution Approach 1:

The differentiation protocol maintains continuous progression through all necessary stages without skipping steps, ensuring that each cellular transition is complete and functional before the next stage begins. This continuous action at controlled speeds produces cells that are both numerous and fully mature, rather than accelerating through incomplete differentiation.

Inventive Principle:
Principle #20Continuity of useful action

Solution Approach 2:

The protocol systematically changes culture parameters including growth factor concentrations, inhibitor dosing, and incubation conditions at each stage to optimize differentiation speed while maintaining maturity. By adjusting these parameters precisely, the method achieves high productivity without sacrificing the functional characteristics of mature beta cells.

Inventive Principle:
Principle #35Parameter changes

3Adaptability or versatility

If polyhormonal cells are produced, then multiple hormone types are expressed, but the cells are non-functional and do not respond appropriately to glucose

Engineering Contradiction:
Improvehormone expression diversityVSAvoidglucose responsiveness
Core Design Contradiction:
Adaptability or versatilityVSReliability

Solution Approach 1:

The method extracts and eliminates unnecessary hormone expression programs through selective inhibition of signaling pathways that would lead to polyhormonal differentiation. By removing these alternative differentiation paths, only the insulin-positive beta cell program survives, resulting in functionally mature cells with appropriate glucose responsiveness rather than non-functional polyhormonal cells.

Inventive Principle:
Principle #2Taking out (Extraction)

Data Source

PatentEP2794857B1Differentiation of human embryonic stem cells into single hormonal insulin positive cells
Publication Date: 2026.02.11 JANSSEN BIOTECH INC
  • EP2794857B1 patent drawingFigure 1A~1D
  • EP2794857B1 patent drawingFigure 1E~1G
  • EP2794857B1 patent drawingFigure 2A~2D

AI summary

The present invention provides methods to promote the differentiation of pluripotent stem cells. In particular, the present invention provides methods to produce a population of cells, wherein greater than 10% of the cells in the population express markers characteristic of single hormonal pancreatic beta cells.